Management of rare fungal infections

Current Opinion in Infectious Diseases

Volumn 17, Issue 6, 2004, Pages 527-532

  Al Abdely, Hail M ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b MBC 46 ^*  (Saudi Arabia)

Author keywords

Antifungal; Fusarium; Mycosis; Penicillium marneffie; Phaeohyphomycosis; Rare fungi; Scedosporium; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; COTRIMOXAZOLE; DEFEROXAMINE; ECHINOCANDIN B DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; IRON CHELATING AGENT; ITRACONAZOLE; KETOCONAZOLE; POTASSIUM IODIDE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BASIDIOBOLOMYCOSIS; BRAIN DISEASE; CANCER PATIENT; CHRONIC GRANULOMATOUS DISEASE; DEBRIDEMENT; DIABETES MELLITUS; DISEASE ASSOCIATION; ENTOMOPHTHORAMYCOSIS; FUNGUS; FUSARIOSIS; GASTROINTESTINAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MORTALITY; MOUSE; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PENICILLIUM MARNEFFEI; PHAEOHYPHOMYCETES; PHAEOHYPHOMYCOSIS; RARE DISEASE; REVIEW; SCEDOSPORIOSIS; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM PROLIFICANS; SOUTHEAST ASIA; TRAVEL; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; FUSARIUM; HUMANS; MYCOSES; PENICILLIUM; SCEDOSPORIUM; ZYGOMYCOSIS;

EID: 10344238984     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200412000-00004     Document Type: Review

References (74)

1. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 (Suppl 1):48-66. A very good review of many recently emerging pathogenic fungi. It details the microbiological and clinical features as well as therapeutic options.
2. Brandt ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother 2003; 15 (Suppl 2):36-47. A comprehensive review of infections caused by dematiaceous fungi. All clinical entities are included, which range from cutaneous, sinus to cerebral and disseminated disease.
3. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38:206-216. An excellent review of almost all cases of cerebral phaeohyphomycosis reported in the literature. A total of 101 cases. C. bantiana was the most common (48%) followed by R. mackenziei (13%). It reviews the clinical features, therapy and outcome of these cases.
4. Kantarcioglu AS, de Hoog GS. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses 2004; 47:4-13. Another good and comprehensive review of recent cases of cerebral phaeohyphomycosis.
5. Revankar SG, Patterson JE, Sutton DA, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34:467-476.
6. Khan ZU, Lamdhade SJ, Johny M, et al. Additional case of Ramichloridium mackenziei cerebral phaeohyphomycosis from the Middle East. Med Mycol 2002; 40:429-433.
7. Kanj SS, Amr SS, Roberts GD. Ramichloridium mackenziei brain abscess: report of two cases and review of the literature. Med Mycol 2001; 39:97-102.
8. Podnos YD, Anastasio P, De La Maza L, Kim RB. Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): case report. Neurosurgery 1999; 45:372-375.
9. Sutton DA, Slifkin M, Yakulis R, Rinaldi MG. US case report of cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (R. mackenziei): criteria for identification, therapy, and review of other known dematiaceous neurotropic taxa. J Clin Microbiol 1998; 36:708-715.
10. Al-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichloridium mackenziei'). Antimicrob Agents Chemother 2000; 44:1159-1162.
11. Johnson EM, Szekely A, Warnock DW. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother 1999; 43:1260-1263.
12. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42:741-745.
13. Singh N, Chang FY, Gayowski T, Marino IR. Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis 1997; 24:369-374.
14. Vukmir RB, Kusne S, Linden P, et al. Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient. Clin Infect Dis 1994; 19:714-719.
15. Al-Mohsen IZ, Sutton DA, Sigler L, et al. Acrophialophora fusispora brain abscess in a child with acute lymphoblastic leukemia: review of cases and taxonomy. J Clin Microbiol 2000; 38:4569-4576.
16. Sharkey PK, Graybill JR, Rinaldi MG, et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 1990; 23:577-586.
17. Halaby T, Boots H, Vermeulen A, et al. Phaeohyphomycosis caused by Alternaria infectoria in a renal transplant recipient. J Clin Microbiol 2001; 39:1952-1955.
18. Keyser A, Schmid FX, Linde HJ, et al. Disseminated Cladophialophora bantiana infection in a heart transplant recipient. J Heart Lung Transplant 2002; 21:503-505.
19. Safdar A. Curvularia - favorable response to oral itraconazole therapy in two patients with locally invasive phaeohyphomycosis. Clin Microbiol Infect 2003; 9:1219-1223.
20. Fica A, Diaz MC, Luppi M, et al. Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana. Scand J Infect Dis 2003; 35:892-893. A case that demonstrates the difficulty in treating cerebral infection caused by C. bantiana even with the broad-spectrum triazole voriconazole.
21. Trinh JV, Steinbach WJ, Schell WA, et al. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol 2003; 41:339-345. This is a case in which voriconazole and caspofungin were combined for the treatment of C. bantiana.
22. Wang TK, Chiu W, Chim S, et al. Disseminated ochroconis gallopavum infection in a renal transplant recipient: the first reported case and a review of the literature. Clin Nephrol 2003; 60:415-423. A report of a positive response to voriconazole in the treatment of Phaeohyphomycetes.
23. Al-Abdely HM, Najvar L, Bocanegra R, Graybill JR. SCH56592 (SCH) therapy of experimental murine cerebral phaeohyphomycosis due to Cladophialophora bantiana (CB). In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998; San Diego, CA [Abstract no. J-69].
24. Al-Abdely HM, Alkunaizi A, Al-Tawfiq J, et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. In: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, UK: Clinical Microbiology and Infection, 2003 [Abstract no. P548]. The first case of the prolonged survival of R. mackenziei cerebral infection in a renal transplant recipient.
25. Agger WA, Andes D, Burgess JW. Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine. Clin Infect Dis 2004; 38:e112-e115.
26. Ryder NS. Activity of terbinafine against serious fungal pathogens. Mycoses 1999; 42 (Suppl 2):115-119.
27. Odabasi Z, Paetznick VL, Rodriguez JR, et al. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother 2004; 48:1912-1915.
28. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002; 16:895-914, vi.
29. Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994; 19:67-76.
30. Parfrey NA. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine (Baltimore) 1986; 65:113-123.
31. Petrikkos G, Skiada A, Sambatakou H, et al. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 22:753-756.
32. Handzel O, Landau Z, Halperin D. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough? Rhinology 2003; 41:184-186.
33. Mondy KE, Haughey B, Custer PL, et al. Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: case report and literature review. Pharmacotherapy 2002; 22:519-526.
34. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001; 20:460-466.
35. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47:3647-3650.
36. Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46:2310-2312.
37. Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36:1488-1491. A case of mucormycosis that responded to the oral triazole posaconazole.
38. Greenberg R, Herbrecht R, Langston A, et al. Posaconazole therapy of refractory invasive zygomycosis. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003; Chicago, IL [Abstract M-1757]. A case series that demonstrated the efficacy of posaconazole in the treatment of refractory mucormycosis.
39. Jacobs P, Wood L, Du Toit A, Esterhuizen K. Eradication of invasive mucormycosis - effectiveness of the Echinocandin FK463. Hematology 2003; 8:119-123.
40. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (Suppl 1):31-47. A comprehensive review of the microbiology and clinical data on zygomycosis that includes entomophthoramycosis.
41. Gugnani HC. A review of zygomycosis due to Basidiobolus ranarum. Eur J Epidemiol 1999; 15:923-929.
42. Al Jarie A, Al-Mohsen I, Al Jumaah S, et al. Pediatric gastrointestinal basidiobolomycosis. Pediatr Infect Dis J 2003; 22:1007-1014. A detailed description of six cases of basidiobolomycosis of the gastrointestinal tract from Saudi Arabia.
43. Lyon GM, Smilack JD, Komatsu KK, et al. Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature. Clin Infect Dis 2001; 32:1448-1455.
44. Yousef OM, Smilack JD, Kerr DM, et al. Gastrointestinal basidiobolomycosis. Morphologic findings in a cluster of six cases. Am J Clin Pathol 1999; 112:610-616.
45. al-Hajjar S, Perfect J, Hashem F, et al. Orbitofascial conidiobolomycosis in a child. Pediatr Infect Dis J 1996; 15:1130-1132.
46. Krishnan SG, Sentamilselvi G, Kamalam A, et al. Entomophthoromycosis in India - a 4-year study. Mycoses 1998; 41:55-58.
47. Foss NT, Rocha MR, Lima VT, et al. Entomophthoramycosis: therapeutic success by using amphotericin B and terbinafine. Dermatology 1996; 193:258-260.
48. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10 (Suppl 1):67-75.
49. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38:1237-1242.
50. Jensen TG, Gahrn-Hansen B, Arendrup M, Bruun B. Fusarium fungaemia in immunocompromised patients. Clin Microbiol Infect 2004; 10:499-501. A nice review of Fusarium fungemia, with associated features, therapy and outcomes.
51. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909-920.
52. Consigny S, Dhedin N, Datry A, et al. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37:311-313.
53. Guimera-Martin-Neda F, Garcia-Bustinduy M, Noda-Cabrera A, et al. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. Br J Dermatol 2004; 150:777-778.
54. Vincent AL, Cabrero JE, Greene JN, Sandin RL. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control 2003; 10:414-419.
55. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46:3298-3300.
56. Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43:589-591.
57. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86:829-830.
58. Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis 2003; 36:1349-1350.
59. Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J Chemother 2003; 15 (Suppl 2):16-27.
60. Danaher PJ, Walter EA. Successful treatment of chronic meningitis caused by Scedosporium apiospermum with oral voriconazole. Mayo Clin Proc 2004; 79:707-708.
61. Klopfenstein KJ, Rosselet R, Termuhlen A, Powell D. Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med Pediatr Oncol 2003; 41:494-495.
62. Bosma F, Voss A, van Hamersvelt HW, et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect 2003; 9:750-753.
63. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34:1648-1650.
64. Studahl M, Backteman T, Stalhammar F, et al. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr 2003; 92:980-982.
65. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003; 41:3981-3985.
66. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22:111-113.
67. Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46:233-236.
68. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47:106-117.
69. Al-Abdely HM, Graybill JR. Penicilliosis marneffie. In: Guerrant R, Walker D, Weller P, editors. Tropical infectious diseases, principles, pathogens and practice. Philadelphia, PA: Churchill Livingstone; 1999. pp. 641-644.
70. Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37:2407-2411.
71. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339:1739-1743.
72. Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:1107-1110.
73. Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47:1376-1381.
74. Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004; 10 (Suppl 1):76-85. A nice review of some of the less commonly encountered fungi.